Log in to save to my catalogue

Enantioselective metabolism of primaquine by human CYP2D6

Enantioselective metabolism of primaquine by human CYP2D6

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4301821

Enantioselective metabolism of primaquine by human CYP2D6

About this item

Full title

Enantioselective metabolism of primaquine by human CYP2D6

Publisher

England: BioMed Central Ltd

Journal title

Malaria journal, 2014-12, Vol.13 (1), p.507-507, Article 507

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Primaquine, currently the only approved drug for the treatment and radical cure of Plasmodium vivax malaria, is still used as a racemic mixture. Clinical use of primaquine has been limited due to haemolytic toxicity in individuals with genetic deficiency in glucose-6-phosphate dehydrogenase. Earlier studies have linked its therapeutic effects to CY...

Alternative Titles

Full title

Enantioselective metabolism of primaquine by human CYP2D6

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4301821

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4301821

Other Identifiers

ISSN

1475-2875

E-ISSN

1475-2875

DOI

10.1186/1475-2875-13-507

How to access this item